Trending NewsTrending NewsNYSE:BMY Bristol Myers Squibb (BMY) Stock Price, News & Analysis $58.45 +0.14 (+0.25%) Closing price 03:59 PM EasternExtended Trading$58.42 -0.03 (-0.06%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bristol Myers Squibb Stock (NYSE:BMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bristol Myers Squibb alerts:Sign Up Key Stats Today's Range$58.11▼$59.2150-Day Range$55.62▼$61.7952-Week Range$42.52▼$62.89Volume8.55 million shsAverage Volume12.22 million shsMarket Capitalization$119.37 billionP/E Ratio16.42Dividend Yield4.31%Price Target$61.31Consensus RatingHold Company Overview Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics. BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions. Notable products developed or marketed by the company include immune checkpoint inhibitors and combination oncology regimens, anticoagulant therapies, and immunomodulatory agents. The company maintains a sizable R&D organization and invests in clinical development, translational science and collaborative research to expand indications for existing therapies and to advance novel modalities such as targeted agents and cell‑based approaches. The modern Bristol Myers Squibb was formed through the 1989 merger of Bristol‑Myers and Squibb, and it expanded materially with the acquisition of Celgene in 2019, which significantly broadened its hematology and oncology franchise and added a substantial product and pipeline base. BMS has a history of pursuing strategic licensing agreements, partnerships and acquisitions to complement internal discovery efforts and to access new technologies and therapeutic candidates. BMS operates globally, serving patients and healthcare systems across North America, Europe, Asia and other regions through direct commercial operations and partner networks. The company is led by a senior executive team responsible for corporate strategy, R&D and global operations; as of the most recent public disclosures the company’s chief executive officer is Giovanni Caforio. Bristol Myers Squibb continues to prioritize innovation, regulatory engagement and collaborations with academic and industry partners to address unmet medical needs. AI Generated. May Contain Errors. Read More Bristol Myers Squibb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreBMY MarketRank™: Bristol Myers Squibb scored higher than 95% of companies evaluated by MarketBeat, and ranked 24th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingHold Consensus RatingBristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.37, and is based on no strong buy ratings, 8 buy ratings, 10 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBristol Myers Squibb has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bristol Myers Squibb's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-3.80% Earnings GrowthEarnings for Bristol Myers Squibb are expected to decrease by -3.80% in the coming year, from $6.31 to $6.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bristol Myers Squibb is 16.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.50.Price to Earnings Ratio vs. SectorThe P/E ratio of Bristol Myers Squibb is 16.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.71.Price to Earnings Growth RatioBristol Myers Squibb has a PEG Ratio of 0.16. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBristol Myers Squibb has a P/B Ratio of 5.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bristol Myers Squibb's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.54% of the float of Bristol Myers Squibb has been sold short.Short Interest Ratio / Days to CoverBristol Myers Squibb has a short interest ratio ("days to cover") of 3.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bristol Myers Squibb has recently decreased by 3.28%, indicating that investor sentiment is improving. Dividend5.0 / 5Dividend StrengthStrong Dividend LeadershipBristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 4.40%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBristol Myers Squibb has been increasing its dividend for 17 years.Dividend CoverageThe dividend payout ratio of Bristol Myers Squibb is 70.79%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 41.52% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.Read more about Bristol Myers Squibb's dividend. News and Social Media4.4 / 5News Sentiment1.06 News SentimentBristol Myers Squibb has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 48 news articles for Bristol Myers Squibb this week, compared to 13 articles on an average week.Search Interest86 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.MarketBeat Follows50 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 257% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,850,100.00 in company stock.Percentage Held by Insiders0.05% of the stock of Bristol Myers Squibb is held by insiders.Percentage Held by Institutions76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bristol Myers Squibb's insider trading history. Receive BMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMY Stock News Headlines4 stocks to watch on Wednesday: BMY, LOW, NVDA, INTC3 hours ago | seekingalpha.comBristol-Myers taps Anthropic's Claude for 30,000 workers3 hours ago | msn.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 20 at 1:00 AM | Behind the Markets (Ad)BioArctic AB (BRCTF) Q1 2026 Earnings Call Highlights: Strong Sales and Strategic Partnerships ...3 hours ago | finance.yahoo.comBristol-Myers taps Anthropic's Claude for 30,000 workers: reportMay 20 at 8:32 AM | seekingalpha.comBristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global OperationsMay 20 at 8:32 AM | finance.yahoo.comBristol Myers to deploy Anthropic's Claude AI model to speed up drug discoveryMay 20 at 8:32 AM | finance.yahoo.comBristol Myers to deploy Anthropic's Claude AI model to speed up drug discoveryMay 20 at 8:03 AM | reuters.comSee More Headlines BMY Stock Analysis - Frequently Asked Questions How have BMY shares performed this year? Bristol Myers Squibb's stock was trading at $53.93 at the beginning of 2026. Since then, BMY shares have increased by 8.4% and is now trading at $58.4420. How were Bristol Myers Squibb's earnings last quarter? Bristol Myers Squibb Company (NYSE:BMY) released its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The company's revenue was up 2.6% on a year-over-year basis. Read the conference call transcript. When did Bristol Myers Squibb's stock split? Shares of Bristol Myers Squibb split on Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were issued to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Bristol Myers Squibb have any subsidiaries? Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others. Who are Bristol Myers Squibb's major shareholders? Top institutional shareholders of Bristol Myers Squibb include Bank of New York Mellon Corp (1.14%), Dimensional Fund Advisors LP (0.92%), Pzena Investment Management LLC (0.84%) and SG Americas Securities LLC (0.44%). Insiders that own company stock include David V Elkins, Samit Hirawat, Christopher S Boerner, Theodore R Samuels II, Ann Powell, Phil M Holzer, Benjamin Hickey, Robert M Plenge and Bartie Wendy Short. View institutional ownership trends. How do I buy shares of Bristol Myers Squibb? Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bristol Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD). Company Calendar Record date for 5/1 Dividend4/02/2026Ex-Dividend for 5/1 Dividend4/02/2026Last Earnings4/30/2026Dividend Payable5/01/2026Today5/20/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BMY's financial health is in the Green zone, according to TradeSmith. BMY has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceuticals Current SymbolNYSE:BMY CIK14272 Webwww.bms.com Phone(212) 546-4000Fax212-546-4020Employees32,500Year Founded1887Price Target and Rating Average Price Target for Bristol Myers Squibb$61.31 High Price Target$75.00 Low Price Target$40.00 Potential Upside/Downside+4.9%Consensus RatingHold Rating Score (0-4)2.37 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$3.56 Trailing P/E Ratio16.42 Forward P/E Ratio9.26 P/E Growth0.16Net Income$7.05 billion Net Margins15.01% Pretax Margin19.80% Return on Equity64.87% Return on Assets13.16% Debt Debt-to-Equity Ratio2.10 Current Ratio1.42 Quick Ratio1.28 Sales & Book Value Annual Sales$48.19 billion Price / Sales2.48 Cash Flow$8.29 per share Price / Cash Flow7.05 Book Value$9.84 per share Price / Book5.94Miscellaneous Outstanding Shares2,042,070,000Free Float2,041,050,000Market Cap$119.37 billion OptionableOptionable Beta0.26 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:BMY) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran War Update: Trump’s Hand-Written Letter Reveals What Comes NextJim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...Paradigm Press | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bristol Myers Squibb Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Bristol Myers Squibb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
